Dlin-MC3-DMA: Ionizable Lipid Benchmark for Lipid Nanoparticle siRNA and mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is a benchmark ionizable cationic liposome lipid for highly efficient siRNA and mRNA delivery using lipid nanoparticles (LNPs) (Wang et al., 2022). Its structure enables pH-dependent charge switching, facilitating endosomal escape and cytoplasmic release of nucleic acids while minimizing systemic toxicity. Dlin-MC3-DMA LNPs silence hepatic genes with an ED₅₀ of 0.005 mg/kg in mice, approximately 1000-fold more potent than DLin-DMA (Wang et al., 2022). Machine learning models validate its superiority and predict LNP performance based on molecular features. The lipid is insoluble in water and DMSO but dissolves in ethanol at ≥152.6 mg/mL and requires storage at ≤ -20°C (ApexBio).

Biological Rationale

Dlin-MC3-DMA is an ionizable cationic lipid engineered for nucleic acid delivery. Its molecular structure enables reversible protonation. At acidic pH, such as inside endosomes, the lipid becomes positively charged, enhancing interactions with anionic nucleic acids and endosomal membranes (Wang et al., 2022). At physiological pH (7.4), Dlin-MC3-DMA is predominantly neutral, reducing systemic toxicity compared to permanently charged cationic lipids. This duality is critical for safe and efficient delivery of siRNA and mRNA therapeutics. LNPs formulated with Dlin-MC3-DMA, DSPC, cholesterol, and PEGylated lipids provide a robust, clinically validated platform for hepatic gene silencing and vaccine delivery (ApexBio).

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA acts as an ionizable cationic liposome within LNPs. At acidic pH (e.g., pH 5.0–6.5 in endosomes), its tertiary amine group becomes protonated, conferring a positive charge. This promotes electrostatic complexation with negatively charged siRNA or mRNA and destabilization of the endosomal membrane, facilitating endosomal escape. Upon exposure to the cytosol (pH ~7.2), the lipid reverts to a neutral state, minimizing cytotoxicity and off-target effects. The mechanism is central to the efficacy of LNP-mediated gene silencing and vaccination (Wang et al., 2022). Dlin-MC3-DMA’s structure also allows for efficient packaging and protection of nucleic acids during formulation and in systemic circulation.

Evidence & Benchmarks

• Dlin-MC3-DMA LNPs achieve ED₅₀ values of 0.005 mg/kg for hepatic gene silencing in mice, ~1000-fold more potent than DLin-DMA (Wang et al., 2022, DOI).
• Machine learning models trained on 325 LNP formulations identify Dlin-MC3-DMA as a top-performing ionizable lipid for mRNA vaccine delivery (Wang et al., 2022, DOI).
• In vivo, LNPs with Dlin-MC3-DMA at an N/P ratio of 6:1 outperform SM-102 in murine models of mRNA delivery (Wang et al., 2022, DOI).
• Dlin-MC3-DMA is insoluble in water and DMSO but soluble in ethanol at ≥152.6 mg/mL (ApexBio, product page).
• Storage of Dlin-MC3-DMA at ≤ -20°C is recommended; prompt use of prepared solutions is necessary to avoid degradation (ApexBio, product page).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is validated for:

• Lipid nanoparticle siRNA delivery for hepatic gene silencing, e.g., transthyretin (TTR), Factor VII.
• mRNA vaccine formulation, including immunomodulatory and cancer immunochemotherapy applications (Wang et al., 2022).
• Translational research for LNP-mediated gene silencing in animal models and preclinical settings.

This article extends the mechanistic and machine learning-guided insights of "Dlin-MC3-DMA and the Future of Lipid Nanoparticle-Mediate…" by providing atomic, quantitative benchmarks and clarifying LNP workflow integration. It also updates the protocol-focused guidance in "Dlin-MC3-DMA: Optimizing Lipid Nanoparticle siRNA Delivery" with new machine learning validation data.

Common Pitfalls or Misconceptions

• Not suitable for aqueous or DMSO-based formulation: Dlin-MC3-DMA is insoluble in water and DMSO; use ethanol for stock solution preparation (ApexBio).
• Limited to LNP-based delivery: Dlin-MC3-DMA is not validated for polymeric nanoparticle or non-lipid delivery systems.
• Not effective for non-hepatic targeting without additional ligands: LNPs with Dlin-MC3-DMA primarily accumulate in the liver.
• Storage and degradation: Solutions degrade rapidly at higher temperatures; improper storage can compromise activity.
• Not a universal adjuvant: Dlin-MC3-DMA is not immunostimulatory on its own; it serves as a delivery vehicle, not a vaccine adjuvant.

Workflow Integration & Parameters

Dlin-MC3-DMA (A8791) is typically formulated with DSPC, cholesterol, and PEG-DMG at molar ratios optimized for each payload. Ethanol is the recommended solvent for preparing stock solutions at concentrations ≥152.6 mg/mL (ApexBio). The typical N/P ratio (cationic nitrogen to nucleic acid phosphate) for LNP assembly is 6:1, based on murine model optimization (Wang et al., 2022). LNPs should be prepared using microfluidic mixing or ethanol injection, followed by dialysis to remove ethanol and buffer exchange. All solutions must be used promptly; storage at ≤ -20°C is required for the neat lipid. For a comprehensive breakdown of LNP assembly protocols and troubleshooting, see the gold-standard guide here (this article updates machine learning-based optimization parameters).

Conclusion & Outlook

Dlin-MC3-DMA sets the benchmark for ionizable cationic liposome lipids in LNP-based siRNA and mRNA delivery. Its atomic structure, validated by machine learning and in vivo experiments, yields unmatched potency for hepatic gene silencing and mRNA vaccines. Ongoing research explores rational structural modifications and predictive modeling for next-generation LNPs. For reagent sourcing and latest specifications, refer to the Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) product page. For advanced translational insights, compare with this mechanistic analysis, which this article extends by providing new quantitative and workflow-specific guidance.